Khurana Surender, Coyle Elizabeth M, Verma Swati, King Lisa R, Manischewitz Jody, Crevar Corey J, Carter Donald M, Ross Ted M, Golding Hana
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD 20903, USA.
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD 20903, USA.
Vaccine. 2014 Nov 12;32(48):6421-32. doi: 10.1016/j.vaccine.2014.09.049. Epub 2014 Oct 3.
Initiation of mass vaccination is critical in response to influenza pandemic. There is an urgent need of a simple, rapid method for production of influenza vaccine that is more effective than current traditional influenza vaccines. Recent H7N9 transmissions to humans in China with high morbidity/mortality initiated extensive vaccine evaluation. We produced the HA1 domains (amino acids 1-320) from H7N9 and H7N7 strains in E. coli. Both were found to contain primarily monomers/trimers with low oligomeric content. However, when residues from the N-terminal β sheet (first 8 amino acid) of H7 HA1 domains were swapped with the corresponding amino acids from H5N1, functional oligomeric H7 HA1 were produced (HA1-DS), demonstrating strong receptor binding and hemagglutination. In rabbits, the HA1-DS from either H7N9 or H7N7 generated high neutralization titers against both homologous and heterologous H7 strains, superior to the unmodified H7 HA1 proteins. In ferrets, HA1-DS from H7N7 elicited higher (and faster) HI titers, better protected ferrets from lethality, weight loss, and reduced viral loads following challenge with wild-type highly pathogenic H7N7 virus compared with inactivated H7N7 subunit vaccine. HA1-DS vaccinated ferrets were also better protected from weight loss after challenge with the heterologous H7N9 virus compared with inactivated H7N7 subunit vaccine. Importantly, the H7N7 HA1-DS vaccine induced antibody affinity maturation far superior to the inactivated H7N7 subunit vaccine, which strongly correlated with control of viral loads in the nasal washes after challenge with either H7N7 or H7N9 strains. We conclude that N-terminus β sheet domain-swap can be used to produce stable functional oligomeric forms of better recombinant HA1 vaccines in simple, inexpensive bacterial system for rapid response to emerging pandemic threat for the global population.
启动大规模疫苗接种对于应对流感大流行至关重要。迫切需要一种简单、快速的流感疫苗生产方法,该方法要比当前的传统流感疫苗更有效。近期中国出现的高发病率/死亡率的H7N9人传人情况引发了广泛的疫苗评估。我们在大肠杆菌中生产了H7N9和H7N7毒株的HA1结构域(氨基酸1 - 320)。发现两者主要包含低寡聚含量的单体/三聚体。然而,当将H7 HA1结构域N端β折叠(前8个氨基酸)的残基与H5N1的相应氨基酸进行交换时,产生了功能性寡聚H7 HA1(HA1 - DS),表现出强受体结合和血凝活性。在兔子中,来自H7N9或H7N7的HA1 - DS针对同源和异源H7毒株产生了高中和效价,优于未修饰的H7 HA1蛋白。在雪貂中,与灭活的H7N7亚单位疫苗相比,来自H7N7的HA1 - DS引发了更高(且更快)的血凝抑制(HI)效价,能更好地保护雪貂免受致死、体重减轻的影响,并在受到野生型高致病性H7N7病毒攻击后降低病毒载量。与灭活的H7N7亚单位疫苗相比,接种HA1 - DS的雪貂在受到异源H7N9病毒攻击后也能更好地免受体重减轻的影响。重要的是,H7N7 HA1 - DS疫苗诱导的抗体亲和力成熟远优于灭活的H7N7亚单位疫苗,这与在受到H7N7或H7N9毒株攻击后鼻洗液中病毒载量的控制密切相关。我们得出结论,N端β折叠结构域交换可用于在简单、廉价的细菌系统中生产稳定的功能性寡聚形式的更好的重组HA1疫苗,以便对全球人群面临的新出现大流行威胁做出快速反应。